BioWorld

May 15, 2009

View Archived Issues

Cempra Closes $46M Series C for Trials of Two Antibiotics

Cempra Pharmaceuticals Inc. raised $46 million in a Series C financing to continue clinical trials with the two antibiotic programs it licensed three years ago from Optimer Pharmaceuticals Inc. (BioWorld Today) Read More

Economic Downturn Sheds Light on Biotech Value to Communities

Read More

Study: Beta-Catenin is Culprit in Colon Cancer, Not Polyps

Read More

UCB's Anti-TNF Cimzia Gets FDA Nod; Enters Crowded RA Space

Read More

Corrections & Clarifications

Read More

Other News To Note

Read More

Clinic Roundup

Read More